title: Regulation of the lymphocyte adenylate cyclase system by prostaglandin E2 infusions in resistant hypertensive subjects.
abstract: The effects of prostaglandin E2 (PGE2) infusions on the beta 2-adrenoceptor-dependent adenylate cyclase (beta 2ARAC) system of lymphocytes were studied in 26 patients with resistant hypertension (RH). The density of beta 2-adrenoceptors and their affinity for l-isoproterenol were measured with 125ICYP, and adenylate cyclase activity was determined with alpha 32P-ATP in mononuclear lymphocytes of RH patients before and at 1, 7, and 14 days after the last PGE2 infusion. Plasma epinephrine and norepinephrine concentrations were analyzed using high-performance liquid chromatography. The patients were divided into two groups: 19 receiving clonidine (group I) and seven receiving four-drug antihypertensive therapy (group II) before and after PGE2 infusions. Resistance to antihypertensive drugs in patients of both groups was overcome by PGE2 infusions, and was correlated with a decrease in lymphocyte beta 2-adrenoceptor density, an increase in beta 2-receptor affinity for l-isoproterenol, and an increase in adenylate cyclase activation. The absence of a PGE2 effect was associated with an acute increase in plasma epinephrine content and a decrease in the sensitivity of the lymphocyte beta 2ARAC system.
authors.affiliation: USSR Cardiology Research Center, Academy of Medical Sciences of the USSR, Moscow.
authors.forename: T
authors.initials: T
authors.lastname: Krasnikova
authors.forename: V
authors.initials: V
authors.lastname: Minchuna
authors.forename: A
authors.initials: A
authors.lastname: Runikhin
authors.forename: G
authors.initials: G
authors.lastname: Arabidze
authors.forename: A
authors.initials: A
authors.lastname: Mazaev
mesh_terms: D000255:Adenosine Triphosphate / Q000032:analysis; D000262:Adenylyl Cyclases / Q000097:blood* / Q000187:drug effects / Q000502:physiology; D000328:Adult; D002851:Chromatography, High Pressure Liquid; D015232:Dinoprostone / Q000008:administration & dosage / Q000494:pharmacology*; D004837:Epinephrine / Q000097:blood; D006801:Humans; D006973:Hypertension / Q000201:enzymology* / Q000503:physiopathology; D007262:Infusions, Intravenous; D007545:Isoproterenol / Q000378:metabolism; D008214:Lymphocytes / Q000201:enzymology* / Q000502:physiology / Q000648:ultrastructure; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D010761:Phosphorus Radioisotopes; D011943:Receptors, Adrenergic, beta / Q000378:metabolism / Q000502:physiology
chemical_list: D010761:Phosphorus Radioisotopes; D011943:Receptors, Adrenergic, beta; D000255:Adenosine Triphosphate; D000262:Adenylyl Cyclases; D015232:Dinoprostone; D007545:Isoproterenol; D009638:Norepinephrine; D004837:Epinephrine